New York, NY, February 13, 2022 – Abacus Finance Group, LLC – a leading provider of cash flow-based, classic senior debt for sponsor-led buyouts of lower middle-market companies – today announced that it served as Senior Secured Credit Facilities Administrative Agent and Sole Lender for senior secured credit facilities to support the leveraged buyout of Sabai Group, LLC by Thompson Street Capital Partners. Additionally, Abacus made an equity co-investment in Sabai Group, LLC.

Founded in 2017 and headquartered in Chesterfield, MO, Sabai Group, LLC is a provider of regulatory and safety review solutions for clinical trials related to cell and gene therapy. Based in St. Louis, Thompson Street Capital Partners is a middle-market private equity firm that helps transform already-exceptional businesses into market leaders.

“As in past transactions, we were impressed by the Abacus team’s speed of execution and ease of documentation. Once again, they were responsive, flexible, easy to work with, and able to provide certainty of closure early,” said Thompson Street Capital Partners Vice President Mark Chan.

“Our longstanding partnership with Thompson Street Capital Partners, which shares our lower middle-market focus, has become one of our best client relationships,” said Tim Clifford, President and CEO of Abacus. “We know that when they come to us with a transaction, it will involve a high-quality company like Sabai Group, LLC.” “What is important to them – in addition to speed and certainty of close – is our flexibility in structuring transactions and the emphasis we place on exceptional client service – all part of our Total Partnership Approach™,” added Sean McKeever, Abacus Managing Director and COO.

Abacus team members involved in the transaction included Sean McKeever, Joseph Lee, and Greg Scanlon. Legal counsel was provided to Abacus by Goulston & Storrs, PC.

About Sabai Group, LLC

Founded in 2017 and headquartered in Chesterfield, MO, Sabai Group. LLC is a provider of regulatory and safety review solutions for clinical trials related to cell and gene therapy. Cell and gene therapy aims to treat diseases by restoring or altering certain sets of cells or by using cells to carry a therapy through the body or by replacing, inactivating, or introducing genes into cells— either inside the body or outside of the body. Sabai Group, LLC’s services are mission-critical to its pharmaceutical and contract research organization customers as the Food and Drug Administration and National Institutes of Health require review and approvals (prior to starting trial) for a clinical trial’s protocol design and process, biosafety design, and subject protection. For more information, please visit sabai group.com.

About Thompson Street Capital Partners

Thompson Street Capital Partners is a middle-market private equity firm that helps transform already exceptional businesses into market leaders. Based in St. Louis, Missouri, it invests globally in the Life Sciences & Healthcare, Software & Technology, and Business & Consumer Services and Products sectors. It partners with management teams to increase value by accelerating growth, both organically and via complementary acquisitions. For more information, please visit www.tscp.com. 

About Abacus Finance Group, LLC

Abacus Finance is a leading direct lending company, focused on providing cash flow senior financing to private equity/family office-sponsored, lower middle-market companies across diverse industries. Since Abacus’s inception in 2011, it has closed over $3 billion in financings. The firm targets private debt financing opportunities of up to $50 million and finances companies with EBITDA between $3 million and $15 million. Abacus is an affiliate of New York Private Bank & Trust, which was founded in 1850.